A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors.

Trial Profile

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Jul 2011 Planned end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Results reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Synta media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top